Figure 3A shows that CIS patients exhibited a significantly higher frequency of CD4+IFN-γ+ T cells than HC (p = 0.0328) and SPMS (p = 0.0062) and PPMS (p = 0.0314) patients. This evidence concerns the gene CD4 and in situ carcinoma.